How These Essential Oils Help People with Lyme Disease to Fight Drug Resistant Candida

Greg Blog 2 Comments


For people receiving antibiotic treatment for Lyme disease that have impaired brain function, fatigue, and intestinal bloating due to a drug-resistant Candida infection
by Greg Lee

While clearing space for a new flower garden, I found a tangled mass of vines. English ivy had overgrown a large area. Pulling up one vine unearthed four more. After thirty minutes of pulling and digging, most of the vines were cleaned up.

How is a tangled mass of ivy similar to a person with Lyme disease that is fighting a Candida infection?

Just like a bed of fast growing ivy, Candida can quickly spread in patients receiving antibiotics for Lyme disease
There are over twenty species of Candida that can infect humans1. Candida is a yeast that can be ingested on contaminated food. Candida can normally be found along with healthy microbes in the digestion tract. Both exposure to environmental mold which suppresses the immune system and excess consumption of alcohol, sugar, and carbohydrates can increase the growth of Candida. People who have chronic medical conditions, like Lyme disease, are a greater risk of a systemic Candida infection2. Antibiotic therapy for Lyme disease, can kill off healthy gut microbes, which can create more areas in the intestines for Candida to spread into. In some cases, antibiotic therapy in Lyme patients may be combined with steroid3 or immuno-suppressive4 treatment. Studies have shown that people undergoing antibiotic, steroid, or immuno-suppressive treatment are more at risk of a Candida infection5. A chronic Lyme infection can also suppress the immune system, which may also enable Candida to spread deeper6. A systemic Candida infection can mimic the symptoms of Lyme disease.

There is a significant overlap between symptoms of a systemic Candida and Lyme disease infection
A systemic Candida infection can produce similar symptoms as found in patients with Lyme disease. Symptoms which overlap are:

  • Fever and chills7
  • Chronic fatigue8
  • Digestion pain, bloating, and nausea9
  • Meningitis10
  • Headache11
  • Arthritis12
  • Heart arrhythmia13
  • Cognitive decline and memory recall problems14
  • ADHD15
  • Depression16
  • Urinary tract infections17
  • Systemic inflammatory response18
  • Seizures19
  • Death20

Not surprisingly, both Lyme and Candida can trigger the release of similar inflammatory compounds which are associated with increased symptoms.

Both Lyme and Candida infections can trigger the increase of multiple inflammatory compounds
Candida21 and Lyme disease22 infections have been shown to trigger the release of Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Interleukin-8 (IL-8)23, and Interleukin-10 (IL-10)24. IL-1β is implicated in patients with depression25 and joint inflammation26. IL-6 is strongly associated with rheumatoid arthritis27, depression28, hostility29, fatigue30, flu-like symptoms and fever31, and cognitive impairment32. IL-8 is implicated in patients with anxiety33, meningitis34, and spirochete (leptospira) induced liver inflammation35. IL-10 is associated with irritable bowel disease36 and fatigue37. Unfortunately, these infections also employ other mechanisms to help them survive in their hosts.

Candida and Lyme employ multiple mechanisms to survive longer
Both infections are capable of hiding inside of cells38, and infecting the brain39. They can producing biofilms40, which are a slime produced to protect against antimicrobial drugs41, the killer cells of the immune system, and against other pathogens. Biofilms can increase drug resistance by a factor of ten to a thousand fold42. Biofilms are believed to be a main cause of recurring Candida or Lyme disease symptoms that persist despite multiple rounds of antibiotics43 or antifungal medications44. In addition to increased resistance from biofilms, Candida has also developed intrinsic and acquired resistance to multiple antifungal drugs45. In addition to biofilms, Lyme bacteria and Candida are capable of producing proteins that lower the activation of the complement immune response46. The complement immune system is a primary coordinator of the innate and adaptive immune responses for killing invading pathogens47.

What else can help people with Lyme disease to fight a drug-resistant, biofilm forming, immune system manipulating, systemic Candida infection?

Here are four essential oils that are effective at inhibiting stubborn Candida infections
Fortunately, there are essential oils that have been found to inhibit drug resistant Candida, cut through biofilms, and enhance the immune response to invading infections. Some of these oils also help with reducing inflammatory compounds that are elevated in a Lyme and Candida infection. Preparing the remedies in a micronized form called a liposome increases their antimicrobial and antibiofilm properties. High dose liposomal antifungal medications have been safe and effective at treating systemic Candida infections in premature infants48. Since liposomes are so small and are surrounded by a lipid, they have a greater ability to penetrate into cells where these infections can hide. Which is why liposomal remedies may be highly effective at helping patients with eliminating a resistant Candida infection.

Anti-Candida Essential Oil #1: Eucalyptus Essential Oil
In multiple lab studies, eucalyptus essential oil was highly effective at inhibiting the growth of fluconazole resistant Candida biofilms49, inhibited the growth of hospital acquired drug resistant strains of Candida50 and inducing innate cell mediated immune response against infections51. In other studies, eucalyptus oil was effective in relieving post-operative pain52 and inhibiting nitric oxide inflammatory production53. In addition to eucalyptus oil, cinnamon has excellent anti-Candida properties.

Anti-Candida Essential Oil #2: Cinnamon Bark Essential Oil
In multiple studies, cinnamon essential oil is effective at inhibiting Candida albicans54, Candida biofilms55, hospital acquired strains of Candida56, respiratory tract Candida57, and fluconazole-resistant Candida58. When combined in a capsule with patchouli essential oil, 71% of patients infected with an intestinal infection of multiple species of Candida were cured59. Liposomal cinnamon oil was effective at inhibiting drug resistant staphylococcus and it’s biofilms60. Cinnamon oil was effective in lab studies at inhibiting these inflammatory compounds: neurological inducible nitric oxide synthase (iNOS), Cyclooxygenase-2 (COX-2) expression, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inflammation61. Caution: cinnamon oil has produced allergic dermatitis in some cases when placed on the skin. This oil may interfere with blood clotting. In one case, a boy drank 60 ml of cinnamon oil upon a dare and experienced symptoms of burning sensation in the mouth, chest and stomach, dizziness, double vision, nausea, vomiting and later collapsed62. Another promising anti-Candida essential oil is lemongrass.

Anti-Candida Essential Oil #3: Lemongrass Essential Oil
Vaporized Lemongrass oil was 100% effective at inhibiting Candida albicans in a lab study63. In other studies, lemongrass essential oil inhibited multi-drug resistant Candida albicans64, multi-drug resistant strains of Streptococcus and Candida65, and multiple species of Candida66. Lemongrass essential oil has an enhanced killing effect against two species of Candida when combined with silver ions67. Lemongrass oil followed by clove oil was highly effective against Candida albicans and its biofilms68. In one lab study, lemongrass oil inhibited the production of IL-1beta and IL-669. In a human study, lemongrass oil reduced anxiety and tension70. Another spice oil with anti-Candida properties is oregano.

Anti-Candida Essential Oil #4: Oregano Essential Oil
In multiple studies, oregano essential oil was highly effective at inhibiting multiple drug resistant species of Candida71, stopping germination and mycelial growth of Candida albicans in a dose dependent manner72, and inducing cell wall and membrane damage in thirty different strains of Candida albicans73. Oregano oil inhibited IL-1beta, IL-6, GM-CSF, and TNF-alpha inflammatory compounds in a mouse experiment74. Using multiple essential oils in combination can help with reducing systemic Candida infection symptoms and inflammation.

Essential oils in combination can help to resolve systemic Candida infection symptoms in people with Lyme
Similar to clearing out a tangled mass of ivy, essential oils can help people with Lyme to weed out systemic Candida symptoms. Combining these oils together may enhance their anti-Candia and anti-biofilm properties. Patients that have taken these oils combined with a carrier oil under their tongue have reported reduced symptoms of inflammation, improved sleep, and less brain fog.

When encapsulated into a micronized particle called a liposome, these oils may be capable of even greater penetration into the cells, nervous system, and into biofilms where Candida can hide. Through inhibiting the production of inflammatory compounds, these oils may also help with relieving physical symptoms and uncomfortable emotions that are associated with Candida toxins and inflammation. Since some of these essential oils have cautions on their use, work with a Lyme literate essential oil practitioner to develop a proper, safe, and effective strategy for your condition.

– Greg

>> Next step: Click here to take our Stealthy Co-infection Quiz to see which tick infections may be causing your symptoms.

1 “Candidiasis | Types of Diseses | Fungal Diseases | CDC.” Accessed October 10, 2016.
2 “Symptoms | Invasive Candidiasis | Candidiasis | Types of Diseases | Fungal Diseases | CDC.” Accessed October 10, 2016.
3 Takado, Yuhei, Takayoshi Shimohata, Izumi Kawachi, Keiko Tanaka, and Masatoyo Nishizawa. “[Successful treatment of neuroborreliosis with combined administration of
antibiotics and steroids: a case report].” Rinshō Shinkeigaku = Clinical Neurology 52, no. 6 (2012): 411–15.
4 Singh, S. K., and H. J. Girschick. “Lyme Borreliosis: From Infection to Autoimmunity.” Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 10, no. 7 (July 2004): 598–614.doi:10.1111/j.1469-0691.2004.00895.x.
5 Mitrović, S., D. Milosević, D. Dankuc, and R. Jović. “[Mycotic disease of the mucous membranes of the head and neck].” Medicinski Pregled 53, no. 1–2 (February 2000):
6 Diterich, Isabel, Carolin Rauter, Carsten J. Kirschning, and Thomas Hartung. “Borrelia Burgdorferi-Induced Tolerance as a Model of Persistence via Immunosuppression.”
Infection and Immunity 71, no. 7 (July 2003): 3979–87.
7 “Symptoms | Invasive Candidiasis | Candidiasis | Types of Diseases | Fungal Diseases | CDC.” Accessed October 10, 2016.
8 Evengård, Birgitta, Hanna Gräns, Elisabeth Wahlund, and Carl Erik Nord. “Increased Number of Candida Albicans in the Faecal Microflora of Chronic Fatigue Syndrome
Patients during the Acute Phase of Illness.” Scandinavian Journal of Gastroenterology 42, no. 12 (December 2007): 1514–15. doi:10.1080/00365520701580397.
9 Cater, R. E. “Chronic Intestinal Candidiasis as a Possible Etiological Factor in the Chronic Fatigue Syndrome.” Medical Hypotheses 44, no. 6 (June 1995): 507–15.
10 Voice, R. A., S. F. Bradley, J. A. Sangeorzan, and C. A. Kauffman. “Chronic Candidal Meningitis: An Uncommon Manifestation of Candidiasis.” Clinical Infectious Diseases:
An Official Publication of the Infectious Diseases Society of America 19, no. 1 (July 1994): 60–66.
11 Yampolsky, Claudio, Marcelo Corti, and Ricardo Negroni. “Fungal Cerebral Abscess in a Diabetic Patient Successfully Treated with Surgery Followed by Prolonged
Antifungal Therapy.” Revista Iberoamericana De Micología 27, no. 1 (March 31, 2010): 6–9. doi:10.1016/j.riam.2009.12.001.
12 Gamaletsou, Maria N., Blandine Rammaert, Marimelle A. Bueno, Nikolaos V. Sipsas, Brad Moriyama, Dimitrios P. Kontoyiannis, Emmanuel Roilides, et al. “Candida Arthritis: Analysis of 112 Pediatric and Adult Cases.” Open Forum Infectious Diseases 3, no. 1 (January 2016): ofv207. doi:10.1093/ofid/ofv207.
13 Franklin, W. G., A. B. Simon, and T. M. Sodeman. “Candida Myocarditis without Valvulitis.” The American Journal of Cardiology 38, no. 7 (December 1976): 924–28.
14 Severance, Emily G., Kristin L. Gressitt, Catherine R. Stallings, Emily Katsafanas, Lucy A. Schweinfurth, Christina L. Savage, Maria B. Adamos, et al. “Candida Albicans
Exposures, Sex Specificity and Cognitive Deficits in Schizophrenia and Bipolar Disorder.” NPJ Schizophrenia 2 (2016): 16018. doi:10.1038/npjschz.2016.18.
15 Rucklidge, Julia J. “Could Yeast Infections Impair Recovery from Mental Illness? A Case Study Using Micronutrients and Olive Leaf Extract for the Treatment of ADHD and Depression.” Advances in Mind-Body Medicine 27, no. 3 (2013): 14–18.
16 Irving, G., D. Miller, A. Robinson, S. Reynolds, and A. J. Copas. “Psychological Factors Associated with Recurrent Vaginal Candidiasis: A Preliminary Study.” Sexually
Transmitted Infections 74, no. 5 (October 1998): 334–38.
17 Dyess, D. L., R. N. Garrison, and D. E. Fry. “Candida Sepsis. Implications of Polymicrobial Blood-Borne Infection.” Archives of Surgery (Chicago, Ill.: 1960) 120, no. 3
(March 1985): 345–48.
18 Liao, Xuelian, Haibo Qiu, Ruoyu Li, Fengmei Guo, Wei Liu, Mei Kang, Yan Kang, and China-SCAN Team. “Risk Factors for Fluconazole-Resistant Invasive Candidiasis in
Intensive Care Unit Patients: An Analysis from the China Survey of Candidiasis Study.” Journal of Critical Care 30, no. 4 (August 2015): 862.e1-5.
19 Queiroz, L. S., A. Nucci, and J. L. De Faria. “[Systemic candidiasis with localization in the brain. Anatomo-clinical study of 5 cases].” Arquivos De Neuro-Psiquiatria 34, no. 1 (March 1976): 18031.
20 Leroy, Olivier, Jean-Pierre Gangneux, Philippe Montravers, Jean-Paul Mira, François Gouin, Jean-Pierre Sollet, Jean Carlet, et al. “Epidemiology, Management, and Risk
Factors for Death of Invasive Candida Infections in Critical Care: A Multicenter, Prospective, Observational Study in France (2005-2006).” Critical Care Medicine 37, no.
5 (May 2009): 1612–18. doi:10.1097/CCM.0b013e31819efac0.
21 Whiley, Robert A., Alan T. Cruchley, Carelyn Gore, and Eleni Hagi-Pavli. “Candida Albicans Strain-Dependent Modulation of pro-Inflammatory Cytokine Release by in Vitro
Oral and Vaginal Mucosal Models.” Cytokine 57, no. 1 (January 2012): 89–97. doi:10.1016/j.cyto.2011.10.017.
22 Jablonska, Ewa, and Magdalena Marcinczyk. “TLR2 Expression in Relation  to IL-6 and IL-1beta and Their Natural Regulators Production by PMN and PBMC in Patients
with Lyme Disease.” Mediators of Inflammation 2006, no. 1 (2006): 32071. doi:10.1155/MI/2006/32071.
23 Grygorczuk, S., S. Pancewicz, J. Zajkowska, M. Kondrusik, R. Rwierzbińska, and T. Hermanowska-Szpakowicz. “Concentrations of Macrophage Inflammatory Proteins MIP-1alpha and MIP-1beta and Interleukin 8 (Il-8) in Lyme Borreliosis.” Infection 32, no. 6 (December 2004): 350–55. doi:10.1007/s15010-004-3110-4.
24 Lilic, Desa, Ian Gravenor, Neil Robson, David A. Lammas, Pam Drysdale, Jane E. Calvert, Andrew J. Cant, and Mario Abinun. “Deregulated Production of Protective
Cytokines in Response to Candida Albicans Infection in Patients with Chronic Mucocutaneous Candidiasis.” Infection and Immunity 71, no. 10 (October 2003): 5690–
25 Rosa, Araceli, Victor Peralta, Sergi Papiol, Manuel J. Cuesta, Fermín Serrano, Alfredo Martínez-Larrea, and Lourdes Fañanás. “Interleukin-1beta (IL-1beta) Gene and
Increased Risk for the Depressive Symptom-Dimension in Schizophrenia Spectrum Disorders.” American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics:
The Official Publication of the International Society of Psychiatric Genetics 124B, no. 1 (January 1, 2004): 10–14. doi:10.1002/ajmg.b.20074.
26 van Vulpen, Lize F. D., Roger E. G. Schutgens, Katja Coeleveld, Els C. Alsema, Goris Roosendaal, Simon C. Mastbergen, and Floris P. J. G. Lafeber. “IL-1β, in Contrast
to TNFα, Is Pivotal in Blood-Induced Cartilage Damage and Is a Potential Target for Therapy.” Blood 126, no. 19 (November 5, 2015): 2239–46. doi:10.1182/blood-2015-03-
27 Cronstein, Bruce N. “Interleukin-6–a Key Mediator of Systemic and Local Symptoms in Rheumatoid Arthritis.” Bulletin of the NYU Hospital for Joint Diseases 65 Suppl 1
(2007): S11-15.
28 Spalletta, Gianfranco, Luca Cravello, Francesca Imperiale, Francesca Salani, Paola Bossù, Livio Picchetto, Marina Cao, et al. “Neuropsychiatric Symptoms and Interleukin-6
Serum Levels in Acute Stroke.” The Journal of Neuropsychiatry and Clinical Neurosciences 25, no. 4 (2013): 255–63. doi:10.1176/appi.neuropsych.12120399.
29 Suarez, Edward C. “Joint Effect of Hostility and Severity of Depressive Symptoms on Plasma Interleukin-6 Concentration.” Psychosomatic Medicine 65, no. 4 (August 2003): 523–27.
30 Udina, Marc, José Moreno-España, Ricard Navinés, Dolors Giménez, Klaus Langohr, Mònica Gratacòs, Lucile Capuron, Rafael de la Torre, Ricard Solà, and Rocío Martín-
Santos. “Serotonin and Interleukin-6: The Role of Genetic Polymorphisms in IFNInduced Neuropsychiatric Symptoms.” Psychoneuroendocrinology 38, no. 9 (September
2013): 1803–13. doi:10.1016/j.psyneuen.2013.03.007.
31 Kaiser, L., R. S. Fritz, S. E. Straus, L. Gubareva, and F. G. Hayden. “Symptom Pathogenesis during Acute Influenza: Interleukin-6 and Other Cytokine Responses.”
Journal of Medical Virology 64, no. 3 (July 2001): 262–68.
32 Frydecka, Dorota, Błażej Misiak, Edyta Pawlak-Adamska, Lidia Karabon, Anna Tomkiewicz, Paweł Sedlaczek, Andrzej Kiejna, and Jan Aleksander Beszłej. “Interleukin-
6: The Missing Element of the Neurocognitive Deterioration in Schizophrenia? The Focus on Genetic Underpinnings, Cognitive Impairment and Clinical Manifestation.”
European Archives of Psychiatry and Clinical Neuroscience 265, no. 6 (September 2015): 449–59. doi:10.1007/s00406-014-0533-5.
33 Uher, Tomas, and Petr Bob. “Cerebrospinal Fluid IL-8 Levels Reflect Symptoms of Alexithymia in Patients with Non-Inflammatory Neurological Disorders.”
Psychoneuroendocrinology 36, no. 8 (September 2011): 1148–53. doi:10.1016/j.psyneuen.2011.02.006.
34 Ishiguro, A., Y. Suzuki, Y. Inaba, K. Fukushima, A. Komiyama, H. P. Koeffler, and T. Shimbo. “The Production of IL-8 in Cerebrospinal Fluid in Aseptic Meningitis of
Children.” Clinical and Experimental Immunology 109, no. 3 (September 1997): 426–30.
35 Rizvi, M., M. Azam, M. R. Ajmal, I. Shukla, and A. Malik. “Prevalence of Leptospira in Acute Hepatitis Syndrome and Assessment of IL-8 and TNF-Alpha Level in Leptospiral Hepatitis.” Annals of Tropical Medicine and Parasitology 105, no. 7 (October 2011):499–506. doi:10.1179/1364859411Y.0000000041.
36 Shulman, Robert J., Monica E. Jarrett, Kevin C. Cain, Elizabeth K. Broussard, and Margaret M. Heitkemper. “Associations among Gut Permeability, Inflammatory Markers, and Symptoms in Patients with Irritable Bowel Syndrome.” Journal of Gastroenterology 49, no. 11 (November 2014): 1467–76. doi:10.1007/s00535-013-0919-6.
37 Neu, Daniel, Olivier Mairesse, Xavier Montana, Medhi Gilson, Francis Corazza, Nicolas Lefevre, Paul Linkowski, Olivier Le Bon, and Paul Verbanck. “Dimensions of
Pure Chronic Fatigue: Psychophysical, Cognitive and Biological Correlates in the Chronic Fatigue Syndrome.” European Journal of Applied Physiology 114, no. 9
(September 2014): 1841–51. doi:10.1007/s00421-014-2910-1.
38 Bopp, Lawrence H., Aldona L. Baltch, William J. Ritz, Phyllis B. Michelsen, and Raymond P. Smith. “Antifungal Effect of Voriconazole on Intracellular Candida Glabrata,
Candida Krusei and Candida Parapsilosis in Human Monocyte-Derived Macrophages.” Journal of Medical Microbiology 55, no. Pt 7 (July 2006): 865–70.
39 Black, Joseph T. “Cerebral Candidiasis: Case Report of Brain Abscess Secondary to Candida Albicans, and Review of Literature.” Journal of Neurology, Neurosurgery, and
Psychiatry 33, no. 6 (December 1970): 864–70.
40 Sapi, Eva, Scott L. Bastian, Cedric M. Mpoy, Shernea Scott, Amy Rattelle, Namrata Pabbati, Akhila Poruri, et al. “Characterization of Biofilm Formation by Borrelia
Burgdorferi in Vitro.” PloS One 7, no. 10 (2012): e48277. doi:10.1371/journal.pone.0048277.
41 Douglas, L. Julia. “Candida Biofilms and Their Role in Infection.” Trends in Microbiology 11, no. 1 (January 2003): 30–36.
42 Olson, Merle E., Howard Ceri, Douglas W. Morck, Andre G. Buret, and Ronald R. Read. “Biofilm Bacteria: Formation and Comparative Susceptibility to Antibiotics.”
Canadian Journal of Veterinary Research 66, no. 2 (April 2002): 86–92.
43 Sapi, Eva, Navroop Kaur, Samuel Anyanwu, David F. Luecke, Akshita Datar, Seema Patel, Michael Rossi, and Raphael B. Stricker. “Evaluation of in-Vitro Antibiotic
Susceptibility of Different Morphological Forms of Borrelia Burgdorferi.” Infection and Drug Resistance 4 (2011): 97–113. doi:10.2147/IDR.S19201.
44 Kuhn, Duncan M., and Mahmoud A. Ghannoum. “Candida Biofilms: Antifungal Resistance and Emerging Therapeutic Options.” Current Opinion in Investigational
Drugs (London, England: 2000) 5, no. 2 (February 2004): 186–97.
45 Sanguinetti, Maurizio, Brunella Posteraro, and Cornelia Lass-Flörl. “Antifungal Drug Resistance among Candida Species: Mechanisms and Clinical Impact.” Mycoses 58
Suppl 2 (June 2015): 2–13. doi:10.1111/myc.12330.
46 Meri, T., H. Amdahl, M. J. Lehtinen, S. Hyvärinen, J. V. McDowell, A. Bhattacharjee, S. Meri, R. Marconi, A. Goldman, and T. S. Jokiranta. “Microbes Bind Complement
Inhibitor Factor H via a Common Site.” PLoS Pathogens 9, no. 4 (April 2013). doi:10.1371/journal.ppat.1003308.
47 Dunkelberger, Jason R., and Wen-Chao Song. “Complement and Its Role in Innate and Adaptive Immune Responses.” Cell Research 20, no. 1 (December 15, 2009): 34–
50. doi:10.1038/cr.2009.139.
48 Juster-Reicher, A., O. Flidel-Rimon, M. Amitay, S. Even-Tov, E. Shinwell, and E. Leibovitz. “High-Dose Liposomal Amphotericin B in the Therapy of Systemic Candidiasis
in Neonates.” European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 22, no. 10 (October 2003):603–7. doi:10.1007/s10096-003-0993-4.
49 Agarwal, Vishnu, Priyanka Lal, and Vikas Pruthi. “Prevention of Candida Albicans Biofilm by Plant Oils.” Mycopathologia 165, no. 1 (January 2008): 13–19.
50 Warnke, Patrick H., Stephan T. Becker, Rainer Podschun, Sureshan Sivananthan, Ingo N. Springer, Paul A. J. Russo, Joerg Wiltfang, Helmut Fickenscher, and Eugene
Sherry. “The Battle against Multi-Resistant Strains: Renaissance of Antimicrobial Essential Oils as a Promising Force to Fight Hospital-Acquired Infections.” Journal of
Cranio-Maxillo-Facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery 37, no. 7 (October 2009): 392–97. doi:10.1016/j.jcms.2009.03.017.
51 Serafino, Annalucia, Paola Sinibaldi Vallebona, Federica Andreola, Manuela Zonfrillo, Luana Mercuri, Memmo Federici, Guido Rasi, Enrico Garaci, and Pasquale Pierimarchi. “Stimulatory Effect of Eucalyptus Essential Oil on Innate Cell-Mediated Immune Response.” BMC Immunology 9 (2008): 17. doi:10.1186/1471-2172-9-17.
52 Jun, Yang Suk, Purum Kang, Sun Seek Min, Jeong-Min Lee, Hyo-Keun Kim, and Geun Hee Seol. “Effect of Eucalyptus Oil Inhalation on Pain and Inflammatory
Responses after Total Knee Replacement: A Randomized Clinical Trial.” Evidence-Based Complementary and Alternative Medicine: eCAM 2013 (2013): 502727.
53 Vigo, E., A. Cepeda, O. Gualillo, and R. Perez-Fernandez. “In-Vitro Anti-Inflammatory Effect of Eucalyptus Globulus and Thymus Vulgaris: Nitric Oxide Inhibition in J774A.1 Murine Macrophages.” The Journal of Pharmacy and Pharmacology 56, no. 2 (February 2004): 257–63. doi:10.1211/0022357022665.
54 Carvalhinho, Sara, Ana Margarida Costa, Ana Cláudia Coelho, Eugénio Martins, and Ana Sampaio. “Susceptibilities of Candida Albicans Mouth Isolates to Antifungal Agents, Essentials Oils and Mouth Rinses.” Mycopathologia 174, no. 1 (July 2012): 69–76. doi:10.1007/s11046-012-9520-4.
55 Pires, Regina Helena, Lilian Bueno Montanari, Carlos Henrique G. Martins, José Eduardo Zaia, Ana Marisa Fusco Almeida, Marcelo T. Matsumoto, and Maria José S.
Mendes-Giannini. “Anticandidal Efficacy of Cinnamon Oil against Planktonic and Biofilm Cultures of Candida Parapsilosis and Candida Orthopsilosis.” Mycopathologia 172, no. 6 (December 2011): 453–64. doi:10.1007/s11046-011-9448-0.
56 Warnke, Patrick H., Stephan T. Becker, Rainer Podschun, Sureshan Sivananthan, Ingo N. Springer, Paul A. J. Russo, Joerg Wiltfang, Helmut Fickenscher, and Eugene
Sherry. “The Battle against Multi-Resistant Strains: Renaissance of Antimicrobial Essential Oils as a Promising Force to Fight Hospital-Acquired Infections.” Journal of
Cranio-Maxillo-Facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery 37, no. 7 (October 2009): 392–97.
57 Singh, H. B., M. Srivastava, A. B. Singh, and A. K. Srivastava. “Cinnamon Bark Oil, a Potent Fungitoxicant against Fungi Causing Respiratory Tract Mycoses.” Allergy 50, no. 12 (December 1995): 995–99.
58 Soares, I. H., É S. Loreto, L. Rossato, D. N. Mario, T. P. Venturini, F. Baldissera, J. M. Santurio, and S. H. Alves. “In Vitro Activity of Essential Oils Extracted from
Condiments against Fluconazole-Resistant and -Sensitive Candida Glabrata.” Journal De Mycologie Médicale 25, no. 3 (September 2015): 213-17.
59 Wang, Gang-Sheng, Jie-Hua Deng, Yao-Hui Ma, Min Shi, and Bo Li. “Mechanisms, Clinically Curative Effects, and Antifungal Activities of Cinnamon Oil and Pogostemon Oil Complex against Three Species of Candida.” Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine 32, no. 1 (March 2012): 19–24.
60 Cui, Haiying, Wei Li, Changzhu Li, Saritporn Vittayapadung, and Lin Lin. “Liposome Containing Cinnamon Oil with Antibacterial Activity against Methicillin-Resistant
Staphylococcus Aureus Biofilm.” Biofouling 32, no. 2 (2016): 215–25. doi:10.1080/08927014.2015.1134516.
61 Chen, Yuh-Fung, Yu-Wen Wang, Wei-Shih Huang, Ming-Ming Lee, W. Gibson Wood, Yuk-Man Leung, and Huei-Yann Tsai. “Trans-Cinnamaldehyde, An Essential Oil in
Cinnamon Powder, Ameliorates Cerebral Ischemia-Induced Brain Injury via Inhibition of Neuroinflammation Through Attenuation of iNOS, COX-2 Expression and NFκ-B
Signaling Pathway.” Neuromolecular Medicine 18, no. 3 (September 2016): 322–33. doi:10.1007/s12017-016-8395-9.
62 Tisserand, Robert, and Rodney Young. Essential Oil Safety: A Guide for Health Care Professionals. Elsevier Health Sciences, 2013. p. 890.
63 Tyagi, Amit K., and Anushree Malik. “Liquid and Vapour-Phase Antifungal Activities of Selected Essential Oils against Candida Albicans: Microscopic Observations and
Chemical Characterization of Cymbopogon Citratus.” BMC Complementary and Alternative Medicine 10 (2010): 65. doi:10.1186/1472-6882-10-65.
64 Khan, Mohd Sajjad Ahmad, Abida Malik, and Iqbal Ahmad. “Anti-Candidal Activity of Essential Oils Alone and in Combination with Amphotericin B or Fluconazole against
Multi-Drug Resistant Isolates of Candida Albicans.” Medical Mycology 50, no. 1 (January 2012): 33–42. doi:10.3109/13693786.2011.582890.
65 Warnke, Patrick H., Stephan T. Becker, Rainer Podschun, Sureshan Sivananthan, Ingo N. Springer, Paul A. J. Russo, Joerg Wiltfang, Helmut Fickenscher, and Eugene
Sherry. “The Battle against Multi-Resistant Strains: Renaissance of Antimicrobial Essential Oils as a Promising Force to Fight Hospital-Acquired Infections.” Journal of
Cranio-Maxillo-Facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery 37, no. 7 (October 2009): 392–97.
66 Silva, Cristiane de Bona da, Sílvia S. Guterres, Vanessa Weisheimer, and Elfrides E. S. Schapoval. “Antifungal Activity of the Lemongrass Oil and Citral against Candida
Spp.” The Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases 12, no. 1 (February 2008): 63–66.
67 Ahmad, Aijaz, and Alvaro Viljoen. “The in Vitro Antimicrobial Activity of Cymbopogon Essential Oil (Lemon Grass) and Its Interaction with Silver Ions.” Phytomedicine:
International Journal of Phytotherapy and Phytopharmacology 22, no. 6 (June 1, 2015): 657–65. doi:10.1016/j.phymed.2015.04.002.
68 Khan, Mohd Sajjad Ahmad, and Iqbal Ahmad. “Biofilm Inhibition by Cymbopogon Citratus and Syzygium Aromaticum Essential Oils in the Strains of Candida Albicans.”
Journal of Ethnopharmacology 140, no. 2 (March 27, 2012): 416–23. doi:10.1016/j.jep.2012.01.045.
69 Sforcin, J. M., J. T. Amaral, A. Fernandes, J. P. B. Sousa, and J. K. Bastos. “Lemongrass Effects on IL-1beta and IL-6 Production by Macrophages.” Natural Product
Research 23, no. 12 (2009): 1151–59. doi:10.1080/14786410902800681.
70 Goes, Tiago Costa, Fábio Reis Carvalho Ursulino, Thiago Henrique Almeida-Souza, Péricles Barreto Alves, and Flavia Teixeira-Silva. “Effect of Lemongrass Aroma on
Experimental Anxiety in Humans.” Journal of Alternative and Complementary Medicine (New York, N.Y.) 21, no. 12 (December 2015): 766–73. doi:10.1089/acm.2015.0099.
71 Pozzatti, Patrícia, Liliane Alves Scheid, Tatiana Borba Spader, Margareth Linde Atayde, Janio Morais Santurio, and Sydney Hartz Alves. “In Vitro Activity of Essential
Oils Extracted from Plants Used as Spices against Fluconazole-Resistant and Fluconazole-Susceptible Candida Spp.” Canadian Journal of Microbiology 54, no. 11
(November 2008): 950–56. doi:10.1139/w08-097.
72 Manohar, V., C. Ingram, J. Gray, N. A. Talpur, B. W. Echard, D. Bagchi, and H. G. Preuss. “Antifungal Activities of Origanum Oil against Candida Albicans.” Molecular and
Cellular Biochemistry 228, no. 1–2 (December 2001): 111–17.
73 Bona, E., S. Cantamessa, M. Pavan, G. Novello, N. Massa, A. Rocchetti, G. Berta, and E. Gamalero. “Sensitivity of Candida Albicans to Essential Oils: Are They an
Alternative to Antifungal Agents?” Journal of Applied Microbiology, August 29, 2016. doi:10.1111/jam.13282.
74 Bukovská, Alexandra, Stefan Cikos, Stefan Juhás, Gabriela Il’ková, Pavol Rehák, and Juraj Koppel. “Effects of a Combination of Thyme and Oregano Essential Oils on
TNBS-Induced Colitis in Mice.” Mediators of Inflammation 2007 (2007): 23296. doi:10.1155/2007/23296.

Image courtesy: By KENPEI (KENPEI’s photo) [GFDL (, CC-BY-SA-3.0 ( or CC BY-SA 2.1 jp (], via Wikimedia Commons


The medical information on this site is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information is not intended to be patient education, does not create any patient-practitioner relationship, and should not be used as a substitute for professional diagnosis and treatment.

Please consult your health care provider, or contact the Two Frogs Healing Center for an appointment, before making any healthcare decisions or for guidance about a specific medical condition. The Two Frogs Healing Center expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. The Two Frogs Healing Center does not endorse specifically any test, treatment, or procedure mentioned on the site.

By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by the Two Frogs Healing Center. If you do not agree to the foregoing terms and conditions, you should not enter this site.

Comments 2

    1. Post

Leave a Reply

Your email address will not be published. Required fields are marked *